Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Xetra  >  Bayer AG    BAYN   DE000BAY0017


Delayed Quote. Delayed  - 10/21 05:35:25 pm
90.33 EUR   -0.15%
10/20 Hella and covestro present new designs for vehicle lighting
10/14 CONFIRMATION OF : -- Bayer second in Good Company Ranking -- Board o..
10/13 BAYER : Latest clinical data on Bayer mid-stage candidate Vilaprisan..
News SummaryMost relevantAll newsSector news 

Bayer AG : Not intended for U.S. and UK Media - 103rd Annual Meeting American Association for Cancer Research:

share with twitter share with LinkedIn share with facebook
share via e-mail
03/28/2012 | 02:50pm CEST
Wednesday - March 28, 2012

Not intended for U.S. and UK Media - 103rd Annual Meeting American Association for Cancer Research:

Bayer to Present New Data on Oncology Pipeline

New Preclinical Data Evaluating Innovative Compounds will be presented / Growing Research and Development Portfolio

Berlin, March 28, 2012 - Bayer HealthCare today announced that the company will present latest preclinical data that introduce investigational compounds for both therapy and imaging in its oncology pipeline at the American Association for Cancer Research (AACR) 103rd Annual Meeting, March 31 - April 4, 2012, in Chicago, IL. The annual AACR meeting highlights the latest findings in all major areas of cancer research.

This includes currently at Bayer developed investigational agents such as an antibody-drug conjugate (ADC, BAY 94-9343) and a phosphatidylinositol 3-kinase (PI3K) inhibitor (BAY 80-6946). The antibody-drug conjugate Mesothelin-ADC is being developed to target the antigen mesothelin which is selectively expressed on certain tumors. Mesothelin-ADC is developed in collaboration with ImmunoGen Inc. The PI3K inhibitor targets a lipid kinase involved in crucial cellular functions such as tumor cell proliferation and survival signaling. Both investigational agents are now in early clinical development (Phase I) at Bayer.

"Cancer is a complex disease process and as our understanding of these signaling mechanisms deepens, so does our ability to develop innovative, targeted approaches to combat this disease," said Dr. Karl Ziegelbauer, Head of Therapeutic Research Group Oncology/Gynecological Therapy at Bayer HealthCare. "The research data presented at this oncology research conference shows our commitment toward developing a wide variety of investigational agents against signaling pathways with the goal to treat cancer more effectively so patients can live longer."

Bayer has established a broad network with external partners in the area of oncology. Preclinical data from joint projects will be presented at the upcoming AACR meeting in Chicago, such as the bispecific BiTE® antibody (MT112/ BAY 2010112) targeting a prostate specific antigen which is currently being developed in collaboration with Amgen. A strategic partnership with the German Cancer Research Center (DKFZ) focuses on the translation of findings from research into innovative drugs and highlights of preclinical data from this partnership, like the characterization of DNA methyltransferase 3B, will also be presented at the AACR meeting. Another of Bayer's partners, OncoMed Pharmaceuticals Inc., will present new preclinical data on a Frizzled/Wnt pathway antagonist antibody OMP-18R5.

Additionally, preclinical data will also be presented on regorafenib (BAY 73-4506) and Alpharadin (radium-223 chloride), two investigational agents in late stage clinical development at Bayer.

Alpharadin (radium-223 chloride) is an investigational alpha-pharmaceutical in clinical development for cancer patients with bone or skeletal metastases. This investigational agent mimics calcium and targets radium-223 to areas of high bone deposition in and around bone metastases and is developed together with Algeta ASA. It has shown an increase in overall survival in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastasis in a pivotal Phase III trial. Alpharadin has been granted Fast Track status by the U.S. Food and Drug Administration (FDA).

Regorafenib, a novel oral multi-kinase inhibitor of tumor neoangiogenesis is currently being investigated in clinical trials for its potential to treat patients with various tumor types. Regorafenib has shown an increase in overall survival in a Phase III trial in patients with metastatic colorectal cancer who have progressed after approved therapies, including fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy if KRAS WT. The study was stopped early after an interim analysis which resulted in a statistically significant improvement of overall survival. Another ongoing Phase III trial in patients with tyrosine kinase inhibitor refractory gastrointestinal stromal tumors (GIST) is ongoing. The FDA has granted regorafenib Fast Track status for both indications. For GIST, regorafenib has also been granted "Orphan Drug Status". In 2011, Bayer entered into an agreement with Onyx Pharmaceuticals, Inc. under which Onyx will receive a royalty on any future global net sales of regorafenib in oncology.

Data on two PET tracers L-5-F-18-ethoxy-Tryptophan for tumor specific imaging and FSPG (BAY 94-9392), a derivative of L-glutamate for improved diagnosis and staging of certain tumor types will also be shown at the conference.

A total of 15 abstracts evaluating investigational agents in Bayer's pipeline will be presented at AACR.

Poster Presentations
• Tumor specific imaging by L-5-F-18-ethoxy-Tryptophan mediated by LAT1 and IDO1
o Presentation #360, Session: Imaging of Molecular and Cellular Events in Tumors and Tumor Cells

• Comparison of commercially available phosphorylated ERK antibodies for immunohistochemical biomarker analysis
o Presentation #742, Session: Clinical Trials in Radiation Oncology / Regulatory Science

• Potent in vitro and in vivo anti-tumor activity of PI3K inhibitor BAY 80-6946 and MEK inhibitor BAY 86-9766 in preclinical biliary tract cancer models.
o Presentation #869, Session: Kinase and Phosphatase Inhibitors 1

• Antiproliferative effects of DNA methyltransferase 3B depletion are not associated with DNA demethylation.
o Presentation #1036, Session: Chromatin Regulators

• Regorafenib (BAY 73-4506): Anti-metastatic activity in a mouse model of colorectal cancer.
o Presentation #2337, Session: Angiogenesis Inhibitors

• Efficacy and Candidate Biomarker Evaluation for the anti-Mesothelin antibody drug conjugate BAY 94-9343, Mesothelin-ADC in Mesothelin positive preclinical xenograft models.
o Presentation #2726, Session: Biological Therapy Based on Viruses, Antibodies, or Metformin

• BAY 1082439, a highly selective and balanced PI3K
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on BAYER AG
10/20 Hella and covestro present new designs for vehicle lighting
10/17 BAYER : The U.S. Chamber of Commerce (USCC) - Summit
10/14 BAYER : The U.S. Chamber of Commerce (USCC) - Summit
10/14 CONFIRMATION OF SUSTAINABILITY PERFO : -- Bayer second in Good Company Ranking -..
10/13 BAYER : Latest clinical data on Bayer mid-stage candidate Vilaprisan to be prese..
10/12 BAYER : successfully closed syndication of USD 56.9 billion acquisition faciliti..
10/12 COVESTRO : gears up for K 2016
10/10 COVESTRO : wins green award for CO2 in plastics
10/10 DGAP-PVR : Covestro AG: Veröffentlichung gemäß § 26 Abs. 1 WpHG mit dem Ziel der..
10/10 DGAP-PVR : Covestro AG: Release according to Article 26, Section 1 of the WpHG ..
More news
Sector news : Pharmaceuticals - NEC
10/20DJE.ON to Invest $500 Million in Illinois Wind Farm
10/19DJABBOTT LABORATORIES : Labs Swings to Loss After Booking Charge on Mylan Stake --..
10/19DJAbbott Labs Swings to Loss After Booking Charge on Mylan Stake
10/19DJABBOTT LABORATORIES : Labs Swings to Loss After Booking Charge on Mylan Stake
10/19DJPFIZER : J&J Brushes Off Pfizer's Challenge -- WSJ
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
10/22 ArQule Is Undervalued Going Into Catalyst Events
10/21 WALL STREET BREAKFAST : BAT Bids $47B To Buy Out Reynolds American
10/20 Morgan Stanley in line for $120M fee in Bayer-Monsanto deal
10/20 Don't Worry, It's About To Get Worse
10/20 If Democrats Win - Cramer's Mad Money (10/19/16)
Financials (€)
Sales 2016 46 816 M
EBIT 2016 8 532 M
Net income 2016 4 787 M
Debt 2016 15 429 M
Yield 2016 2,96%
P/E ratio 2016 16,13
P/E ratio 2017 13,89
EV / Sales 2016 1,93x
EV / Sales 2017 1,79x
Capitalization 74 698 M
More Financials
Duration : Period :
Bayer AG Technical Analysis Chart | BAYN | DE000BAY0017 | 4-Traders
Full-screen chart
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 107 €
Spread / Average Target 19%
Consensus details
EPS Revisions
More Estimates Revisions
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Johannes M. Dietsch Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Human Resources, Technology & Sustainability
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BAYER AG-21.87%81 300
JOHNSON & JOHNSON10.44%310 358
ROCHE HOLDING LTD.-15.88%202 361
NOVARTIS AG-13.36%198 298
PFIZER INC.-0.31%195 193
MERCK & CO., INC.15.87%169 231
More Results